adc

Discover highlights from Biointron’s Lunch & Learn with MassBio, featuring HTP antibody platforms, alpaca VHH discovery, bispecific antibodies, and ADC development.

Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

AACR 2024 in San Diego spotlighted breakthroughs in cancer research. Biointron shares highlights on antibody therapeutics, discovery platforms, and translational science.

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

From hybridomas to recombinant platforms, antibody production has evolved. Biointron reveals ten insights into methods that ensure reliable supply and scientific progress.

Antibodies defend against disease and power modern biotech. Biointron shares ten fascinating facts that highlight their versatility and impact in research and therapy.

Personalized antibody therapies bring precision to treatment. Biointron highlights how monoclonal antibodies and ADCs target cancer, IBD, and other diseases with improved outcomes.